| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -3.5 | 8.3 |
| EPS (diluted, $ a share) | $-1.98 | $25.99 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: GTBP. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
GT Biopharma, Inc.: key numbers
- Share price
- $3.18Close, Nov 17
- Market cap
- $6.8M
- Shares outstanding
- 2.14MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from GT Biopharma, Inc.
All →GT Biopharma Capital Raise
GT Biopharma shareholders approved a significant increase in authorized common shares from 25 million to 250 million and authorized the issuance of more than 19.99% of outstanding stock. These approvals facilitate the conversion of Series M Preferred Stock and the exercise of warrants related to a Securities Purchase Agreement dated September 14, 2026. The vote ensures compliance with Nasdaq Rule 5635 regarding the potential dilution from these previously announced financing transactions.
GT Biopharma Capital Raise of $7.75M
GT Biopharma amended its securities purchase agreement to increase a private placement of Series M 10% Convertible Preferred Stock and warrants, raising the aggregate purchase price to $7.75 million. The deal includes 'Greenshoe Rights' allowing purchasers to potentially acquire additional preferred stock with an aggregate stated value of up to approximately $34.7 million. The company has committed to filing a registration statement for the resale of the underlying common stock within 30 days of closing.
- Value
- $7.75M
- Counterparty
- New Purchaser
GT Biopharma Capital Raise of $7.45M
GT Biopharma entered into a securities purchase agreement for a private placement of up to 8,277.778 shares of Series M 10% Convertible Preferred Stock and associated warrants for an initial purchase price of $7.45 million. The agreement includes 'Greenshoe Rights' allowing purchasers to acquire additional preferred stock with a stated value of up to $33.33 million for an additional $30 million. The preferred stock is convertible into common stock at an initial conversion price of $6.10 per share.
- Value
- $7.45M